<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://jcp.bmj.com">
<title>Journal of Clinical Pathology recent issues</title>
<link>http://jcp.bmj.com</link>
<description>Journal of Clinical Pathology RSS feed -- recent issues</description>
<prism:publicationName>Journal of Clinical Pathology</prism:publicationName>
<prism:issn>0021-9746</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/381?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/389?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/394?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/399?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/403?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/409?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/419?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/424?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/431?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/437?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/441?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/447?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/452?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/457?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/463?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/466?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/470-a?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/470-b?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/471?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/473-a?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/473-b?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/474-a?rss=1" />
  <rdf:li rdf:resource="http://jcp.bmj.com/cgi/content/short/65/5/474-b?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://hwmaint.jcp.bmj.com/homepage/JCP_95x60.gif" />
</channel>
<image rdf:about="http://hwmaint.jcp.bmj.com/homepage/JCP_95x60.gif">
<title>Journal of Clinical Pathology</title>
<url>http://hwmaint.jcp.bmj.com/homepage/JCP_95x60.gif</url>
<link>http://jcp.bmj.com</link>
</image>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/381?rss=1">
<title><![CDATA[Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/381?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>Mucinous adenocarcinoma (MAC) of the colorectum has been known and studied for many years. The prognostic significance of this histological subtype remains controversial. The authors reviewed the prognostic significance of mucinous differentiation in colorectal cancer.</p>
</sec>
<sec><st>Materials and methods</st>
<p>A systematic web-based search was performed using Web of Knowledge and Medline. Articles published in English, German or French which used the WHO definition of MAC and described cohort studies, case&ndash;control studies or cross-sectional studies comparing survival in patients with MAC and adenocarcinoma (AC) not otherwise specified were included. Data on first author, year of publication, country, number of patients included, prevalence of MAC, % stage IV disease, % disease located in the proximal colon, mean age at presentation, % male patients and 5-year overall survival were extracted from individual studies. A fixed-effects meta-analysis model was used for analysis. The primary outcome was survival, expressed as the HR. Differences between categorical outcome parameters were quantified using the RR and corresponding 95% CI.</p>
</sec>
<sec><st>Results</st>
<p>44 studies and 222 256 patients were included. The RR for proximal disease versus distal disease was 1.55 (95% CI 1.53 to 1.58). Mucinous differentiation was less frequent in male subjects (RR 0.93 (95% CI 0.91 to 0.94)). Interestingly, the prevalence of stage IV disease was similar in MAC and AC (RR 0.99 (95% CI 0.96 to 1.02)). Thirty-five articles were included in the survival analysis. A worse survival in MAC versus AC was demonstrated (HR 1.05 (95% CI 1.02 to 1.08)). Conversely, three out of four studies reported a better survival in MAC with microsatellite instability (MSI). Due to heterogeneity a meta-analysis on the effect of MSI was not possible.</p>
</sec>
<sec><st>Conclusion</st>
<p>MAC more often originates from the right colon and is less frequent in male subjects. The authors did not identify a difference in the proportion of stage IV patients at presentation. Mucinous differentiation results in a 2&ndash;8% increased hazard of death, which persists after correction for stage. More research is needed to define the interaction between mucinous differentiation, MSI and outcome.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Verhulst, J., Ferdinande, L., Demetter, P., Ceelen, W.]]></dc:creator>
<dc:date>2012-04-23T15:40:15-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200340</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200340</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Colon cancer]]></dc:subject>
<dc:title><![CDATA[Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Review</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>381</prism:startingPage>
<prism:endingPage>388</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/389?rss=1">
<title><![CDATA[Quality standards and samples in genetic testing]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/389?rss=1</link>
<description><![CDATA[
<p>The most critical performance indicator for medical laboratories is the delivery of accurate test results. In any laboratory, there is always the possibility that random or systematic errors may occur and place human health and welfare at risk. Laboratory quality assurance programmes continue to drive improvements in analytical accuracy. The most rigorously scrutinised data on laboratory errors, which come from transfusion medicine, reveal that the incidence of analytical errors has fallen to levels where most of the residual risk is now found in preanalytical links in the chain from patient to result, particularly activities associated with ordering of tests and sample collection. This insight is important for genetic testing because, like pretransfusion testing of patients with unknown blood groups, a substantial proportion of genotyping results cannot be immediately verified. An increasing number of clinical decisions, associated personal and social choices, and legal outcomes are now influenced by genetic test results in the absence of other confirmatory data. An incorrect test result may lead to unnecessary and irreversible interventions, which may in themselves have associated risks for the patient, inaccurate risk assessment regarding the disease, missed opportunities for disease prevention or even wrongful conviction in a court of law. Unfortunately, there is limited information available about the risk of preanalytical errors associated with, and few published guidelines regarding, sample collection for genetic testing. The growing number and range of important decisions made on the basis of genetic findings warrant a reappraisal of current standards to minimise risks in genetic testing.</p>
]]></description>
<dc:creator><![CDATA[Ravine, D., Suthers, G.]]></dc:creator>
<dc:date>2012-04-23T15:40:15-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200519</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200519</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Unlocked, Editor's choice]]></dc:subject>
<dc:title><![CDATA[Quality standards and samples in genetic testing]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Viewpoint</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>389</prism:startingPage>
<prism:endingPage>393</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/394?rss=1">
<title><![CDATA[Infantile haemangioma expresses embryonic stem cell markers]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/394?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>The origin of infantile haemangioma (IH) remains enigmatic. A primitive mesodermal phenotype origin of IH with the ability to differentiate down erythropoietic and terminal mesenchymal lineages has recently been demonstrated.</p>
</sec>
<sec><st>Aims</st>
<p>To investigate the expression of human embryonic stem cell (hESC) markers in IH and to determine whether IH-derived cells have the functional capacity to form teratoma <I>in vivo</I>.</p>
</sec>
<sec><st>Methods</st>
<p>Immunohistochemical staining and quantitative reverse transcription PCR were used to investigate the expression of hESC markers in IH biopsies. The ability of cells derived from proliferating IH to form teratomas in a mouse xenograft model was investigated.</p>
</sec>
<sec><st>Results</st>
<p>The hESC markers, Oct-4, STAT-3 and stage-specific embryonic antigen 4 were collectively expressed on the endothelium of proliferating IH lesions, whereas Nanog was not. Nanog was expressed by cells in the interstitium and these cells did not express Oct-4, stage-specific embryonic antigen 4 or STAT-3. Proliferating IH-derived cells were unable to form teratomas in severely compromised immunodeficient/non-obese diabetic mice.</p>
</sec>
<sec><st>Conclusion</st>
<p>The novel expression of hESC on two different populations of cells in proliferating IH and their inability to form teratomas <I>in vivo</I> infer the presence of a primitive cellular origin for IH downstream from hESC.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Itinteang, T., Tan, S. T., Brasch, H. D., Steel, R., Best, H. A., Vishvanath, A., Jia, J., Day, D. J.]]></dc:creator>
<dc:date>2012-04-23T15:40:15-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200462</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200462</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Clinical diagnostic tests, Ethics]]></dc:subject>
<dc:title><![CDATA[Infantile haemangioma expresses embryonic stem cell markers]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>394</prism:startingPage>
<prism:endingPage>398</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/399?rss=1">
<title><![CDATA[Clinicopathological significance of podocalyxin and phosphorylated ezrin in uterine endometrioid adenocarcinoma]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/399?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>Podocalyxin is an anti-adhesive glycoprotein that has been associated with highly aggressive forms of cancers. Podocalyxin increases the migration and invasive properties of cancer cells through its interaction with ezrin, which undergoes an increase in phosphorylation through podocalyxin.</p>
</sec>
<sec><st>Aims</st>
<p>To study the roles of podocalyxin and phosphorylated ezrin (pEzrin) in uterine endometrioid adenocarcinoma (UEA).</p>
</sec>
<sec><st>Methods</st>
<p>Using immunohistochemisty the authors investigated the expression of podocalyxin and pEzrin along with some well-known markers of tumour aggressiveness including p53, oestrogen receptor and Ki-67 in UEA.</p>
</sec>
<sec><st>Results</st>
<p>Podocalyxin and pEzrin expression levels were positive in 36.1% (22 of 61 patients) and 50.8% (31 of 61 patients) of UEA cases, respectively. Further, podocalyxin expression was correlated with tumour grade (p=0.0001), FIGO stage (p=0.0062), p53 expression (p=0.0050) and Ki-67 index (p=0.0069). In addition, pEzrin expression was associated with FIGO stage (p=0.0231), p53 expression (p&lt;0.0001) and Ki-67 index (p=0.0010). The expression of podocalyxin was also correlated with that of pEzrin (p=0.0102).</p>
</sec>
<sec><st>Conclusions</st>
<p>These results suggest that overexpression of podocalyxin and pEzrin may indicate a more aggressive phenotype; thus, evaluation of these proteins may be useful in prediction of disease progression in UEA cases.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Yasuoka, H., Tsujimoto, M., Inagaki, M., Kodama, R., Tsuji, H., Iwahashi, Y., Mabuchi, Y., Ino, K., Sanke, T., Nakamura, Y.]]></dc:creator>
<dc:date>2012-04-23T15:40:15-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200359</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200359</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Breast cancer]]></dc:subject>
<dc:title><![CDATA[Clinicopathological significance of podocalyxin and phosphorylated ezrin in uterine endometrioid adenocarcinoma]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>399</prism:startingPage>
<prism:endingPage>402</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/403?rss=1">
<title><![CDATA[Observer agreement comparing the use of virtual slides with glass slides in the pathology review component of the POSH breast cancer cohort study]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/403?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>(1) To compare the use of scanned virtual slide images (virtual microscopy) with glass slides (conventional microscopy) in the assessment of morphological characteristics of breast cancers within the setting of the Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH), involving a cohort of women under 40 years of age, presenting with breast cancer. (2) To assess the acceptability to histopathologists of the use of virtual slide images.</p>
</sec>
<sec><st>Methods</st>
<p>13 histopathologists from the UK and Australia participated in the POSH pathology review. The observers were asked to assess multiple morphological features such as tumour grade and type. Comparisons were made for a single observer using both virtual images and glass slides. Intra- and inter-observer variability was calculated using the  statistic and a comparison was made between the use of each image modality.</p>
</sec>
<sec><st>Results</st>
<p>Diagnostic performance with virtual slides was comparable to conventional microscopic assessment, with the measurement of agreement best for vascular invasion, necrosis and the presence of a central scar (=0.37&ndash;0.78), and poor for more subjective parameters such as pleomorphism, stroma, the nature of the tumour border and the degree of lymphocytic infiltrate (=0.1).</p>
</sec>
<sec><st>Conclusion</st>
<p>Virtual slides represent an acceptable methodology for central review of breast cancer histopathology and can circumvent the need for either travel to view material, or the potential problems of sending it by post.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Shaw, E. C., Hanby, A. M., Wheeler, K., Shaaban, A. M., Poller, D., Barton, S., Treanor, D., Fulford, L., Walker, R. A., Ryan, D., Lakhani, S. R., Wells, C. A., Roche, H., Theaker, J. M., Ellis, I. O., Jones, J. L., Eccles, D. M.]]></dc:creator>
<dc:date>2012-04-23T15:40:15-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200369</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200369</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Breast cancer, Histopathology, Clinical diagnostic tests]]></dc:subject>
<dc:title><![CDATA[Observer agreement comparing the use of virtual slides with glass slides in the pathology review component of the POSH breast cancer cohort study]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>403</prism:startingPage>
<prism:endingPage>408</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/409?rss=1">
<title><![CDATA[Adverse reactions to metal debris: histopathological features of periprosthetic soft tissue reactions seen in association with failed metal on metal hip arthroplasties]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/409?rss=1</link>
<description><![CDATA[
<sec><st>Aim</st>
<p>To describe the histopathology of localised adverse reactions to metal debris (ARMD) seen in association with failed metal on metal (MoM) hip arthroplasties. The nature of aseptic lymphocytic vasculitis associated lesion (ALVAL) is investigated.</p>
</sec>
<sec><st>Methods</st>
<p>Periprosthetic soft tissues biopsied at time of revision from failed MoM hip arthroplasties from January 2007 to March 2011 were analysed. The inflammatory cell response was categorised into perivascular lymphocytic cuffing (ALVAL), lymphoid aggregate formation with or without germinal centres, metallosis characterised by sheets of macrophages with intracytoplasmic metallic debris and well-defined granulomas.</p>
</sec>
<sec><st>Results</st>
<p>123 patient samples were analysed, 36 males (29.2%) and 87 females (70.8%). Three cases showing complete tissue necrosis were excluded. Patients were reviewed between 3.27 to 69.6 months postarthroplasty, with an average of 30.92 months. 103 cases (85.8%) showed ALVAL, 18 cases also showed well-defined granulomas. Of the 103 cases with ALVAL, 60 cases also showed a diffuse chronic lymphocytic synovitis, and 40 cases showed lymphoid aggregates with germinal centres. 17 cases (14.2%) showed pure metallosis. Small vessels showing ALVAL expressed peripheral node addressin.</p>
</sec>
<sec><st>Conclusions</st>
<p>ARMD is a spectrum of changes comprising of pure metallosis, ALVAL and granulomatous inflammation. ALVAL, a distinctive inflammatory response seen in ARMD, is a precursor of lymphoid neogenesis. Lymphoid neogenesis documented in a variety of chronic inflammatory conditions most probably contributes to tissue necrosis and prosthetic failure seen in MoM hip arthroplasties. The role of vascular changes in contributing to necrosis is unclear at this stage.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Natu, S., Sidaginamale, R. P., Gandhi, J., Langton, D. J., Nargol, A. V. F.]]></dc:creator>
<dc:date>2012-04-23T15:40:15-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200398</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200398</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Immunology (including allergy), Histopathology, Inflammation, Degenerative joint disease, Musculoskeletal syndromes, Vascularitis]]></dc:subject>
<dc:title><![CDATA[Adverse reactions to metal debris: histopathological features of periprosthetic soft tissue reactions seen in association with failed metal on metal hip arthroplasties]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>409</prism:startingPage>
<prism:endingPage>418</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/419?rss=1">
<title><![CDATA[The neurofibromin 1 type I isoform predominance characterises female population affected by sporadic breast cancer: preliminary data]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/419?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>Neurofibromin 1 (NF1) as a tumour suppressor gene can give rise to several transcripts by an alternative splicing event, generated at least for CELF cofactors. At present, the NF1 isoforms and CELF splicing transcripts in sporadic breast cancer are unknown. The aim of the authors was to detect NF1 gene expression, the NF1 isoform ratio and the CELF transcripts present in sporadic breast cancer.</p>
</sec>
<sec><st>Methods</st>
<p>Neurofibromin and RAS expression were analysed on tissue microarrays containing sporadic breast cancer (n=22), benign lesions (n=18, including six fibroadenomas, six fibrocystic changes and six ductal hyperplasias) and normal breast tissue (n=6) by immunohistochemistry assay. NF1 and CELF 3&ndash;6 RNA expression was performed by end point reverse transcription-PCR in the breast samples.</p>
</sec>
<sec><st>Results</st>
<p>NF1 and RAS expression in breast tissues showed no differential expression by immunohistochemistry results. Interestingly, the authors observed a shift transition in the isoform transcripts, from type II in normal breast tissue to type I isoform in breast carcinomas. CELF cofactor expression failed to be related with the shift transition of NF1 in breast tissues.</p>
</sec>
<sec><st>Conclusions</st>
<p>These data suggest that there is a tendency for an NF1 expression shift transition from type II to type I isoform, which could comprise a significant event in the development and progression of sporadic breast cancer. This shift transition may not be related with CELF cofactors.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Marrero, D., Peralta, R., Valdivia, A., De la Mora, A., Romero, P., Parra, M., Mendoza, N., Mendoza, M., Rodriguez, D., Camacho, E., Duarte, A., Castelazo, G., Vanegas, E., Garcia, I., Vargas, C., Arenas, D., Jimenez, F., Salcedo, M.]]></dc:creator>
<dc:date>2012-04-23T15:40:15-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200569</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200569</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Molecular genetics, Breast cancer]]></dc:subject>
<dc:title><![CDATA[The neurofibromin 1 type I isoform predominance characterises female population affected by sporadic breast cancer: preliminary data]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>419</prism:startingPage>
<prism:endingPage>423</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/424?rss=1">
<title><![CDATA[Nuclear survivin is associated with cell proliferative advantage in uterine cervical carcinomas during radiation therapy]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/424?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>Although the anticancer effects of radiation therapy for patients with uterine cervical squamous cell carcinoma (U-SCC) are widely acknowledged, little is known about the resultant morphological alterations in tumour tissue kinetics.</p>
</sec>
<sec><st>Aims</st>
<p>To make a detailed assessment of possible roles of survivin expression in apoptosis and cell proliferation in U-SCC during radiation therapy.</p>
</sec>
<sec><st>Methods</st>
<p>181 biopsy specimens from 55 consecutive U-SCCs of patients receiving radiation therapy were studied using a combined morphological (apoptosis) and immunohistochemical (MIB-1 and survivin) approach. The intracellular distribution of various splice variants of the <I>survivin</I> gene was also examined.</p>
</sec>
<sec><st>Results</st>
<p>Tumour cell proliferation, determined as MIB-1 labelling indices (LIs), as well as nuclear survivin (N-Surv) LIs, were inversely correlated with irradiation dosage, in contrast to relatively minor changes in apoptotic indices, suggesting a shift in tumour tissue kinetics towards a relative predominance of cell deletion. In addition, the low N-Sur LI category showed significant stepwise decrease in MIB-1 LIs during therapy, in contrast to no changes in the high category. Exogenous overexpression of three variants of the <I>survivin</I> gene resulted in different expression patterns, showing cytoplasmic staining with or without dot formation for survivin and survivin-2B and distinct nuclear accumulation for survivin-deled exon 3 (Ex3).</p>
</sec>
<sec><st>Conclusions</st>
<p>Results showed that nuclear survivin, including survivin itself and the survivin-Ex3 splice variants, may participate in modulation of altered cell kinetics of U-SCC during radiation therapy.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Chaopotong, P., Kajita, S., Hashimura, M., Saegusa, M.]]></dc:creator>
<dc:date>2012-04-23T15:40:15-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200477</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200477</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Molecular genetics, Cervical cancer, Cervical screening, Gynecological cancer, Clinical diagnostic tests]]></dc:subject>
<dc:title><![CDATA[Nuclear survivin is associated with cell proliferative advantage in uterine cervical carcinomas during radiation therapy]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>424</prism:startingPage>
<prism:endingPage>430</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/431?rss=1">
<title><![CDATA[Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: association with features of differentiation]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/431?rss=1</link>
<description><![CDATA[
<sec><st>Aim</st>
<p>This study was undertaken to evaluate the expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma.</p>
</sec>
<sec><st>Methods and results</st>
<p>Material tested included 111 operated samples and 47 additional biopsy samples consisting of 26 cases of pancreatitis, 3 cases of pancreatic intraepithelial neoplasia and 18 ductal adenocarcinomas. Samples were stained with antibodies to claudins 7 and 18 and analysed for membranous and cytoplasmic expression. Membrane bound claudin 7 and 18 expression was detected in 62 of 105 (59%) and 78 of 111 (70%) cases, respectively. Membrane bound claudin 7 and 18 were associated with large or intermediate neoplastic ducts (p=0.01, p=0.002, respectively). Well differentiated pancreatic adenocarcinomas displayed more cases with membrane bound claudin 7 or 18 immunopositivity (p=0.003, p=0.03, respectively). All pancreatic intraepithelial neoplasias studied expressed membrane bound claudin 18. Membrane bound claudin 7 or 18 positivity was not associated with survival (p=0.17, p=0.98). In the biopsy cases membrane bound claudin 18 had 100% specificity and 51% sensitivity for a tumour marker.</p>
</sec>
<sec><st>Conclusion</st>
<p>Claudin 7 and 18 expression is related to gland size of neoplastic cells and is especially found in tumours with intermediate and large ducts and well differentiated tumours. Membrane bound claudin 18, when present, is a useful marker for diagnosis of pancreatic cancer. Claudins 7 and 18 were not associated with patient survival or spread of tumours.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Soini, Y., Takasawa, A., Eskelinen, M., Juvonen, P., Karja, V., Hasegawa, T., Murata, M., Tanaka, S., Kojima, T., Sawada, N.]]></dc:creator>
<dc:date>2012-04-23T15:40:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200400</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200400</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Pancreas and biliary tract, Pancreatitis, Pancreatic cancer, Clinical diagnostic tests]]></dc:subject>
<dc:title><![CDATA[Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: association with features of differentiation]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>431</prism:startingPage>
<prism:endingPage>436</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/437?rss=1">
<title><![CDATA[The value of triple antibody (34{beta}E12 + p63 + AMACR) cocktail stain in radical prostatectomy specimens with crushed surgical margins]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/437?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>Triple antibody cocktail immunohistochemical staining is routinely used as an ancillary method to establish a diagnosis of prostate cancer in biopsies with small foci of atypical glands. Crush artefact can distort surgical margins in radical prostatectomy specimens, occasionally making it difficult to diagnose a positive margin.</p>
</sec>
<sec><st>Aim</st>
<p>To investigate the ability of a cocktail stain to distinguish carcinoma from benign prostatic glands at the edge of crushed margins in prostatectomy specimens.</p>
</sec>
<sec><st>Methods</st>
<p>10 radical prostatectomy specimens with crushed benign glands at the surgical margins, and 20 with crushed margins positive for carcinoma were retrieved from the pathology archives. The latter included 16 (80%) with positive apical margins, 2 (10%) incised intraprostatic margins, and 1 (5%) soft tissue margin. Two-colour triple antibody stain using a cocktail of antibodies against &alpha;-methylacyl coenzyme A racemase (AMACR), high molecular weight keratin and p63 was performed on all the selected cases.</p>
</sec>
<sec><st>Results</st>
<p>In 10/10 specimens with crushed benign glands, basal cell staining continued to be detectable, while AMACR staining was negative in all cases (0/10). In the positive margin cases, none of the crushed glands expressed basal cell marker staining (0/20), whereas 14/20 (70%) of the cases showed variable levels of AMACR positivity at the inked margin.</p>
</sec>
<sec><st>Conclusion</st>
<p>Two-colour triple antibody cocktail stain is useful in the assessment of most, but not all, surgical margins with crushed artefact in prostatectomy specimens by helping to establish whether glands are malignant or benign.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Daoud, N. A., Li, G., Evans, A. J., van der Kwast, T. H.]]></dc:creator>
<dc:date>2012-04-23T15:40:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200533</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200533</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Prostate cancer, Urological cancer, Clinical diagnostic tests]]></dc:subject>
<dc:title><![CDATA[The value of triple antibody (34{beta}E12 + p63 + AMACR) cocktail stain in radical prostatectomy specimens with crushed surgical margins]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>437</prism:startingPage>
<prism:endingPage>440</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/441?rss=1">
<title><![CDATA[Metaplastic breast cancer: clinicopathological features and its prognosis]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/441?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>The prognosis of metaplastic breast cancer (MBC) is reportedly worse than that of triple-negative invasive ductal carcinoma (TN-IDC), but the determinants of poor prognosis are not yet known.</p>
</sec>
<sec><st>Methods</st>
<p>Patients from two Korean cancer centres were included in this study (67 MBC and 520 TN-IDC). Characteristics of the two disease groups, including clinical parameters, histological features, chemoresponsiveness, disease recurrence and survival estimates, were evaluated.</p>
</sec>
<sec><st>Results</st>
<p>MBC presented with larger tumours, more frequent distant metastasis and higher histological grade compared with TN-IDC (p&lt;0.001). All but nine patients with MBC had triple-negative disease. Disease-free survival and overall survival (OS) of MBC were worse than TN-IDC (p&lt;0.001). Multivariable analysis of disease-free survival revealed MBC type as an independent prognostic factor (HR 2.53; 95% CI 1.32 to 4.84) along with lymph node metastasis and implementation of breast conserving surgery. For OS, MBC type remained a significant prognostic factor (HR 2.56; 95% CI 1.18 to 5.54). Chemoresponsiveness of MBC and TN-IDC were similar in both neoadjuvant (p=1.000) and advanced disease settings (p=0.508). For a given MBC type, risk factors for disease recurrence included the presence of a squamous component (HR 4.0; 95% CI 1.46 to 10.99) and lymph node metastasis (HR 4.76; 95% CI 1.67 to 13.60); the risk factor for OS was initial distant metastasis (HR 10.77; 95% CI 2.59 to 44.76).</p>
</sec>
<sec><st>Conclusions</st>
<p>MBC had worse survival outcomes compared with TN-IDC. Poor prognosis for MBC was likely caused by frequent recurrence with high initial stage and the unique biology of MBC itself.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Lee, H., Jung, S.-Y., Ro, J. Y., Kwon, Y., Sohn, J. H., Park, I. H., Lee, K. S., Lee, S., Kim, S. W., Kang, H. S., Ko, K. L., Ro, J.]]></dc:creator>
<dc:date>2012-04-23T15:40:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200586</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200586</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Immunology (including allergy), Breast cancer]]></dc:subject>
<dc:title><![CDATA[Metaplastic breast cancer: clinicopathological features and its prognosis]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>441</prism:startingPage>
<prism:endingPage>446</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/447?rss=1">
<title><![CDATA[Aetiological relationships of nasal mucus cyclic nucleotides in patients with taste and smell dysfunction]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/447?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>The authors previously demonstrated that nasal mucus cyclic adenosine 3', 5'-monophosphate (cAMP) and cyclic 3', 5'-guanosine monophosphate (cGMP) were lower in patients with smell and taste dysfunction than in normal individuals. To learn more about these differences this study related levels of nasal mucus cAMP and cGMP in patients with smell and taste dysfunction to the aetiology of their sensory loss and compared these results with those in normal individuals.</p>
</sec>
<sec><st>Methods</st>
<p>Nasal mucus cAMP and cGMP levels in patients with smell loss (hyposmia) were calculated after assembling data into aetiological groups. Levels were compared with each clinical group, with the entire patient group and with normal individuals. Data were obtained from initial values among patients with hyposmia who participated in a clinical trial of treatment with the phosphodiesterase inhibitor theophylline.</p>
</sec>
<sec><st>Results</st>
<p>Nasal mucus cyclic nucleotides in the entire patient group before treatment were below normal as previously demonstrated. Stratification by aetiology revealed differences not previously apparent. In some groups levels of cAMP and cGMP were below normal, some were similar to normal and some were above the normal mean.</p>
</sec>
<sec><st>Conclusions</st>
<p>As nasal mucus cyclic nucleotides relate to the growth and development of olfactory epithelial cells these results indicate there are differential alterations in nasal mucus cAMP and cGMP related to the aetiology of smell and taste dysfunction.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Henkin, R. I., Velicu, I.]]></dc:creator>
<dc:date>2012-04-23T15:40:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2012-200698</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2012-200698</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Aetiological relationships of nasal mucus cyclic nucleotides in patients with taste and smell dysfunction]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>447</prism:startingPage>
<prism:endingPage>451</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/452?rss=1">
<title><![CDATA[Application of the UK NHS Improvement Anticoagulation Commissioning Support Document for 'safety indicators' in atrial fibrillation. Results of the European Action on Anticoagulation study]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/452?rss=1</link>
<description><![CDATA[
<sec><st>Introduction</st>
<p>'Safety indicators' in the anticoagulant management of atrial fibrillation (AF) are listed in the UK NHS Improvement Document, &lsquo;Anticoagulation for AF&rsquo;, aiming to promote quality services. Acceptable clinical event rates are not quantified in the document.</p>
</sec>
<sec><st>Objective</st>
<p>To provide clinical evaluation of the relevant safety indicators using data from a recent large European Action on Anticoagulation (EAA) study.</p>
</sec>
<sec><st>Results</st>
<p>469 clinical events were recorded in 5839 outpatients in the EAA study. The safety indicators listed in the NHS Improvement Document were related to these patients with AF. The relevance of the &lsquo;safety indicators&rsquo; is confirmed by the EAA study for patients starting oral anticoagulation and for those already receiving oral anticoagulation, and quantified.</p>
</sec>
<sec><st>Conclusion</st>
<p>The EAA clinical study provides a quantitative basis for the safety indicators' in AF listed in the NHS Commissioning Support Document and emphasises the importance of the document.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Poller, L., Jespersen, J., Cowan, C., Baglin, T., George, J., Ibrahim, S. A.]]></dc:creator>
<dc:date>2012-04-23T15:40:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200587</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200587</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Application of the UK NHS Improvement Anticoagulation Commissioning Support Document for 'safety indicators' in atrial fibrillation. Results of the European Action on Anticoagulation study]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>452</prism:startingPage>
<prism:endingPage>456</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/457?rss=1">
<title><![CDATA[Determination of serum aldosterone by liquid chromatography and tandem mass spectrometry: a liquid-liquid extraction method for the ABSCIEX API-5000 mass spectrometry system]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/457?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>Accurate serum aldosterone determination is critical to the screening and diagnosis of primary aldosteronism, the localisation of aldosterone producing tumours, and the investigation of other disorders of the renin-angiotensin system. Mass spectrometry offers a means to overcome problems with method-dependent bias between competitive immunoassays for aldosterone. The authors have developed a simple, sensitive and precise liquid&ndash;liquid extraction aldosterone method for the ABSCIEX API-5000 liquid chromatography and tandem mass spectrometry (LC-MS/MS) system.</p>
</sec>
<sec><st>Methods</st>
<p>Using d7-aldosterone internal standard, 500&nbsp;&mu;l of sample is extracted with 2500&nbsp;&mu;l of methyl tertbutyl ether followed by dry-down, reconstitution and LC-MS/MS analysis in ESI negative mode. Method validation was undertaken using standard approaches and comparison made against a commercial radioimmunoassay. Accuracy was assessed using EQA material with assigned aldosterone concentrations.</p>
</sec>
<sec><st>Results</st>
<p>The assay was linear up to 3420&nbsp;pmol/l (LOQ=50&nbsp;pmol/l, LOD&lt;22&nbsp;pmol/l). Total CVs were &le;5% for concentrations &ge;120&nbsp;pmol/l and 10% at the LOQ. Mean accuracy was 98.5% against GCMS assigned material.</p>
</sec>
<sec><st>Conclusion</st>
<p>The authors present a precise, sensitive and simple aldosterone method suitable for routine clinical use that requires no solid phase extraction or specialised ion sources.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Van Der Gugten, J. G., Dubland, J., Liu, H.-F., Wang, A., Joseph, C., Holmes, D. T.]]></dc:creator>
<dc:date>2012-04-23T15:40:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200564</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200564</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Immunology (including allergy), Adrenal disorders]]></dc:subject>
<dc:title><![CDATA[Determination of serum aldosterone by liquid chromatography and tandem mass spectrometry: a liquid-liquid extraction method for the ABSCIEX API-5000 mass spectrometry system]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>457</prism:startingPage>
<prism:endingPage>462</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/463?rss=1">
<title><![CDATA[The relationship between serum TSH and free T4 in older people]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/463?rss=1</link>
<description><![CDATA[
<p>The frequency distribution of serum thyroid stimulating hormone (TSH) shows a skewed pattern that may change with age. The set point of the hypothalamic-pituitary-thyroid axis for an individual is thought to be genetically determined and has been described as a log-linear relationship of serum TSH to free thyroxine (T4); however, the validity of this hypothesis has yet to be established in older people. The aim of the study was to describe the relationship between serum TSH and free T4 in older people and define factors influencing this relationship. We conducted a cross-sectional, observational study of thyroid function in a community population of older subjects over 65&nbsp;years of age. The relationship between serum TSH and free T4 was not linear as previously described, but is best described as a fourth-order polynomial. Both gender and smoking status affected the relationship. This suggests that more complex modelling is required when investigating the hypothalamic-pituitary-thyroid axis.</p>
]]></description>
<dc:creator><![CDATA[Clark, P. M., Holder, R. L., Haque, S. M., Hobbs, F. D. R., Roberts, L. M., Franklyn, J. A.]]></dc:creator>
<dc:date>2012-04-23T15:40:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200433</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200433</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[The relationship between serum TSH and free T4 in older people]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Short report</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>463</prism:startingPage>
<prism:endingPage>465</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/466?rss=1">
<title><![CDATA[Delineation of the infrequent mosaicism of KRAS mutational status in metastatic colorectal adenocarcinomas]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/466?rss=1</link>
<description><![CDATA[
<p>This study addresses the extent of the heterogeneity of <I>KRAS</I> status, present in a minority of metastatic colorectal carcinomas (mCRCs), on the basis of a thorough analysis of surgical resection specimens. Eighteen patients with mCRC were included. <I>KRAS</I> mutations (exon 2, codons 12 and 13) were determined using PCR and subsequent direct sequencing. This analysis included primary tumours (n=21), synchronous (n=10) and metachronous (n=18) matched metastases, and pelvic recurrence (n=1). Heterogeneity of <I>KRAS</I> status consisted in <I>KRAS</I> mutated in (i) the primary tumour but not in its synchronous metastasis, (ii) the metastasis but not in the primary tumour, (iii) the pelvic recurrence but not in the primary tumour, (iiii) some metastases and not in others from the same patient. Finally, the <I>KRAS</I> status varied among different areas of the same metastatic focus. This study defines the concept of <I>KRAS</I> mosaicism that affects a minority of mCRCs.</p>
]]></description>
<dc:creator><![CDATA[Bossard, C., Kury, S., Jamet, P., Senellart, H., Airaud, F., Ramee, J.-F., Bezieau, S., Matysiak-Budnik, T., Laboisse, C. L., Mosnier, J.-F.]]></dc:creator>
<dc:date>2012-04-23T15:40:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200608</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200608</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Molecular genetics, Colon cancer]]></dc:subject>
<dc:title><![CDATA[Delineation of the infrequent mosaicism of KRAS mutational status in metastatic colorectal adenocarcinomas]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Short report</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>466</prism:startingPage>
<prism:endingPage>469</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/470-a?rss=1">
<title><![CDATA[Authors' response - The prognostic benefits of routine staining with elastica to increase detection of venous invasion in colorectal cancer specimens]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/470-a?rss=1</link>
<description><![CDATA[ <p>The recent study by Roxburgh <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> is the first to demonstrate that the routine use of an elastin stain to detect venous invasion (VI) in colorectal cancer specimens is a better predictor of long-term outcome than a standard H&amp;E stain alone. It is interesting to note that the threefold increase in the detection of VI observed by these authors following the introduction of routine elastin staining was applicable to a group of general pathologists. Both in North America and the UK, the provision of colorectal cancer services is not centralised and institutions that offer exclusive reporting of colorectal cancer specimens by subspecialist gastrointestinal (GI) pathologists are in the minority. Clearly, the general, or non-specialist GI, pathologist still has an important role to play in the reporting of colorectal cancer specimens.</p> <p>Our study revealed that subspecialist GI pathologists were more likely to report higher VI detection rates...]]></description>
<dc:creator><![CDATA[Messenger, D. E., Driman, D. K., Kirsch, R.]]></dc:creator>
<dc:date>2012-04-23T15:40:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200438</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200438</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Authors' response - The prognostic benefits of routine staining with elastica to increase detection of venous invasion in colorectal cancer specimens]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>470</prism:startingPage>
<prism:endingPage>470</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/470-b?rss=1">
<title><![CDATA[Editorial: MMP-2 and MMP-9 in lymph-node-positive bladder cancer]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/470-b?rss=1</link>
<description><![CDATA[ <p>The paper by Seiler <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> describes tissue microarrays on tissue taken from 150 patients with invasive bladder cancer. These patients were clinically node negative on preoperative staging, but were found to have nodal metastases on subsequent histopathological examination. Patients had not received neoadjuvant chemotherapy. The median lymph node yield of 27 is a surrogate for thorough lymphadenectomy and careful histopathological processing. The authors set out to study variation in expression in MMP-2 and MMP-9 expression in non-malignant bladder, tumour centre, tumour edge and nodal metastasis. This was to examine the potential role of these MMP in invasion and metastasis. Their results show no clear-cut relationship between these MMP and invasion front. Boxplots of expression were overlapping between benign, primary tumour and nodal metastasis. Levels of MMP-2 and MMP-9 increase between benign and malignant bladder tissue. For MMP-2 the level drops again for lymph node; whereas for...]]></description>
<dc:creator><![CDATA[Hegarty, P. K.]]></dc:creator>
<dc:date>2012-04-23T15:40:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200360</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200360</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Editorial: MMP-2 and MMP-9 in lymph-node-positive bladder cancer]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>470</prism:startingPage>
<prism:endingPage>471</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/471?rss=1">
<title><![CDATA[A prospective pilot survey of the impact of general practitioner generated full blood count requests on clinical haematology workload: a London teaching hospital experience]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/471?rss=1</link>
<description><![CDATA[ <p>Workload measurement is critical for planning, programming and staffing an organisation.<cross-ref type="bib" refid="b1">1</cross-ref> Rising consumer expectation, the growing and ageing population and the increases in the number and technical sophistication of medical interventions have increased the workload in haematology laboratories as in other laboratory specialities,<cross-ref type="bib" refid="b2">2</cross-ref> <cross-ref type="bib" refid="b3">3</cross-ref> both from primary and secondary care. Since 1996, the National Pathology Benchmarking Study has conducted annual cycles of comparative analysis of the workload and organisation of haematology departments in the UK.<cross-ref type="bib" refid="b4">4</cross-ref> In the current economic climate and with the trend towards laboratory centralisation, many laboratories are moving the analysis of general practitioner (GP)-requested samples to central laboratories. However, there are no studies that specifically aimed to determine the laboratory workload generated by the GP requests and the clinical haematology workload specifically emanating from GP-requested samples. Full blood count (FBC) analysis is a commonly requested laboratory investigation by...]]></description>
<dc:creator><![CDATA[Islam, M. S., Sharma, B., Sullivan, K., Hunt, B. J.]]></dc:creator>
<dc:date>2012-04-23T15:40:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200260</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200260</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[A prospective pilot survey of the impact of general practitioner generated full blood count requests on clinical haematology workload: a London teaching hospital experience]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>471</prism:startingPage>
<prism:endingPage>473</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/473-a?rss=1">
<title><![CDATA[Detection of Y chromosomal material in ovarian (gonadal) tumours]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/473-a?rss=1</link>
<description><![CDATA[ <p>I read the article by Shahsiah and colleagues with interest.<cross-ref type="bib" refid="b1">1</cross-ref> The authors analysed 47 ovarian germ cell tumours for the presence of testis-specific protein Y-encoded (TSPY) using a PCR technique and identified significant levels of TSPY in seven cases. The importance of identifying Y chromosomal material in these cases, and in phenotypic women generally, is that such patients have increased risk of developing bilateral ovarian/gonadal tumours. These most commonly, but not exclusively, take the form of germ cell neoplasms and often are associated with gonadoblastoma which may be regarded as a form of in situ neoplasia.</p> <p>One problem encountered by the authors in their analysis of archival paraffin-embedded tumour tissues was that these frequently showed low-level contamination with Y chromosomal material and therefore it was necessary to use a relative quantitative PCR technique to establish reliable cut-off values between genuine and spurious levels of Y chromosome content....]]></description>
<dc:creator><![CDATA[Stewart, C. J. R.]]></dc:creator>
<dc:date>2012-04-23T15:40:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200527</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200527</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Detection of Y chromosomal material in ovarian (gonadal) tumours]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>473</prism:startingPage>
<prism:endingPage>473</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/473-b?rss=1">
<title><![CDATA[Interpretation of clonality and X-chromosome inactivation assays urge attention]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/473-b?rss=1</link>
<description><![CDATA[ <p>There is a huge debate on the clonal origin of solid tumours. Since clonality has strong implications in the molecular diagnosis used to characterise the mutations that are important in personalised medicine, we highlight two serious recurrent misinterpretation issues regarding clonality. First, monotypy in X-inactivation assays is being repeatedly interpreted as monoclonality. Second, it is time we stop considering monoclonality as a bona fide characteristic of a tumour.</p> <p>The size of the clonal field is crucial to support the leap from monotypy at an X-inactivation assay to monoclonality, as a large clonal field size may confound assessment of tumour clonality with X-inactivation assays.<cross-ref type="bib" refid="b1">1</cross-ref> This drawback is clear, making the misinterpretation of monotypy in X-linked gene assays as monoclonality unacceptable.</p> <p>Another important caveat perpetuated is that all neoplasias are clonal. At present, all the definite evidence is on the side of polyconal tumour origin. Colon tumours, for example,...]]></description>
<dc:creator><![CDATA[Gomes, C. C., Gomez, R. S.]]></dc:creator>
<dc:date>2012-04-23T15:40:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200526</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200526</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Interpretation of clonality and X-chromosome inactivation assays urge attention]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>473</prism:startingPage>
<prism:endingPage>473</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/474-a?rss=1">
<title><![CDATA[The Last Time]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/474-a?rss=1</link>
<description><![CDATA[ <p><qd><p>The lecture hall is full,</p> <p>The students are keen,</p> <p>It's the last lecture</p> <p>And there are tips to glean.</p> <p>The lecturer aware of the expectant air</p> <p>Is careful to choose his words with care.</p> </qd></p> <p><qd><p>Correct the papers, pass or fail?</p> <p>First class honours the holy grail</p> <p>Some answers too long, full of packing,</p> <p>Others too short, facts sadly lacking.</p> <p>Occasionally, a student bright</p> <p>Lights up a page like a shaft of light!</p> <p>Easy to read, straight to the core,</p> <p>Harmony and logic like a Mozart score.</p> </qd></p> <p><qd><p>Time for a viva, one last time,</p> <p>Have to decide who's first past the line.</p> <p>Gaze in turn at each nervous face</p> <p>And wonder if they will stick the pace.</p> <p>The Extern, aloof and steely eyed,</p> <p>As I present our best with pride.</p> </qd></p> <p><qd><p>Like a tennis match he begins the game,</p> <p>Answers vary, questions the same!</p> <p>Some unsure start to...]]></description>
<dc:creator><![CDATA[Connolly, C. E.]]></dc:creator>
<dc:date>2012-04-23T15:40:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jclinpath-2011-200458</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jclinpath-2011-200458</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[The Last Time]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>474</prism:startingPage>
<prism:endingPage>474</prism:endingPage>
</item>
<item rdf:about="http://jcp.bmj.com/cgi/content/short/65/5/474-b?rss=1">
<title><![CDATA[Correction]]></title>
<link>http://jcp.bmj.com/cgi/content/short/65/5/474-b?rss=1</link>
<description><![CDATA[
<p><b>Sanders SA</b>, Smith AP, Carr RA, <I>et al</I>. Enhanced BMS cut up role in colonic cancer reporting. <I>J Clin Pathol</I> Published Online First: 16 September 2009 doi:<addart type="err" doi="10.1136/jcp.2009.069039">10.1136/jcp.2009.069039</addart>. This article was published online first as an author-supplied PDF. It has since been replaced with the online first publication of the typeset PDF (doi:10.1136/jclinpath-2011-200625).</p>
]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2012-04-23T15:40:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/jcp.2009.069039</dc:identifier>
<dc:identifier>hwp:master-id:jclinpath;jcp.2009.069039</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Correction]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>65</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>474</prism:startingPage>
<prism:endingPage>474</prism:endingPage>
</item>
</rdf:RDF>
